Importance Many investigational drugs fail in late-stage clinical development. A better
understanding of why investigational drugs fail can inform clinical practice, regulatory …

Background/aims: Tragedies suggest that phase I trials in healthy participants may be highly
risky. This possibility raises concern that phase I trials may exploit healthy participants to …

Background Studies measuring the completeness and consistency of trial registration and
reporting rely on linking registries with bibliographic databases. In this systematic review, we …

Objective To investigate the distribution, design characteristics, and dissemination of clinical
trials by funding organisation and medical specialty. Design Cross sectional descriptive …

We assessed the extent to which the publication of clinical trial results of innovative cell-
based interventions reflects International Society for Stem Cell Research best practice …

Background Many new molecular entities enter clinical development to evaluate potential
therapeutic benefits for oncology patients. We characterized adult and pediatric …

Cardiovascular disease remains a leading cause of death, but stakeholders have recently
raised concerns about the pace of innovation and investment in develo** new …

Failure in cancer drug development exacts heavy burdens on patients and research
systems. To investigate inefficiencies and burdens in targeted drug development in cancer …

The high rates of attrition that occur in drug development are widely regarded as
problematic, but the failure of well-designed studies benefits both researchers and …

The Belmont Report has provided a useful and virtually universal framework for protecting
human subjects from research abuses. However, it provides little to no guidance on the …